Log in or Sign up for Free to view tailored content for your specialty!
Cirrhosis/Liver Failure News
Binge drinking, genetic predisposition linked to sixfold higher risk for cirrhosis
Heavy binge drinking and high polygenic risk score were associated with a sixfold higher relative excess risk for alcohol-related cirrhosis, with the presence of diabetes mellitus further increasing the risk, researchers reported.
Oral androgen receptor agonist improves sarcopenia, encephalopathy in cirrhosis
BOSTON — LPCN 1148, an oral androgen receptor agonist, improved sarcopenia, hepatic encephalopathy and other biomarkers associated with end-stage liver disease among men with advanced cirrhosis and clinical decompensation.
Log in or Sign up for Free to view tailored content for your specialty!
Pegozafermin improves stage 4 fibrosis, noninvasive markers in MASH patients
BOSTON — Pegozafermin improved fibrosis and other key noninvasive tests at 24 weeks in patients with metabolic dysfunction-associated steatohepatitis-related cirrhosis, according to data presented at The Liver Meeting.
Risk for cirrhosis 50% higher in young women after first episode of alcoholic hepatitis
BOSTON — Female adolescents and young adults have higher rates of liver-related mortality and a 50% higher risk for cirrhosis and decompensation after surviving their first presentation of alcoholic hepatitis, according to data.
ENLIVEN extension topline data: Pegozafermin sustains ‘robust benefits’ in NASH at week 48
Topline findings from an extension of the phase 2b ENLIVEN trial showed that pegozafermin sustained improvements in fibrosis and disease resolution for patients with nonalcoholic steatohepatitis at 48 weeks, 89bio announced.
Naltrexone improves liver-related parameters, decompensation in alcohol use disorder
BOSTON — Oral naltrexone 50 mg safely improved alcohol use-related parameters and decompensation, and also reduced cravings, over 1 year among patients with alcohol use disorder and compensated cirrhosis, according to a presenter.
VIDEO: TERN-501 ‘could be a best-in-class molecule’ alone, as combination therapy for MASH
BOSTON — Treatment with TERN-501, a selective thyroid hormone receptor beta agonist, reduced liver fat content and fibro-inflammation among patients with presumed metabolic dysfunction-associated steatohepatitis, late-breaking data showed.
Provider training alone may not be enough to improve advanced care planning
BOSTON — An educational program for transplant nurse coordinators did not improve advanced care planning among patients with decompensated cirrhosis, suggesting that provider training alone is “insufficient” to create significant change.
ACLF with recompensated cirrhosis has ‘generally milder’ severity, better prognosis
Patients with acute-on-chronic liver failure and recompensated cirrhosis had less severe disease, lower incidence of respiratory failure and better prognosis at 1 year vs. those with decompensated cirrhosis, researchers reported.
Replacing meat with plant, dairy protein curbs ammonia generation in cirrhosis
VANCOUVER, British Columbia — Substituting just one meat-based meal with protein from plant or dairy sources could improve metabolite signatures linked to hepatic encephalopathy in patients with cirrhosis, according to a presenter here.
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read
-
Headline News
Burnout, withdrawal remain ‘alarmingly high’ among physicians and residents
September 17, 20242 min read -
Headline News
Over one-third of adults not planning on receiving recommended vaccines this fall
September 18, 20242 min read -
Headline News
Popular home BP devices unable to provide accurate readings for millions due to sizing
September 19, 20242 min read